A MULTI-CENTER, OPEN-LABEL EXTENSION STUDY OF SUBCUTANEOUS SECUKINUMAB TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY IN POLYMYALGIA RHEUMATICA (PMR)

Registry ID

CAIN457C22301E1

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2024-12-10

Last update

2024-07-04

Conditions

• POLYMYALGIA RHEUMATICA

View on source registry